Retatrutide Canada: All About The Triple Agonist Weight Loss Treatment

Updated October 5, 2026

Injectable medicines such as semaglutide and tirzepatide have changed how Canadians approach diabetes and obesity treatment, with different approved uses depending on the product. Retatrutide, a promising new drug currently undergoing clinical trials, is another treatment being investigated.

Retatrutide is a new injectable medication being developed by Eli Lilly. Known as a “triple agonist,” it targets three hormone receptors at once. In the first Phase 3 trial to report results, the 12 mg group lost an average of 28.7% of body weight at 68 weeks under the trial’s efficacy analysis. The population and alternative analysis are explained below; this was not a comparison with another medicine.

Retatrutide remains unapproved in Canada, and a Canadian approval or pharmacy launch date has not been confirmed. In this comprehensive guide, we’ll cover what Canadians should know about Retatrutide, including what the research shows so far, what remains unknown about cost, potential side effects, and more.

What Is Retatrutide?

Retatrutide, also known by its research name LY3437943, is a weekly injectable medication being developed by Eli Lilly (the same company behind Mounjaro). Like other medications in this class, it works by mimicking hormones your body naturally produces to regulate appetite and blood sugar.

What sets Retatrutide apart is that it’s a “triple agonist.” Related incretin medicines target either one receptor (GLP-1 alone, like Ozempic) or two receptors (GLP-1 and GIP, like Mounjaro). Retatrutide targets all three: GLP-1, GIP, and glucagon.

This triple agonist approach is why retatrutide is generating so much attention. Activating three receptors is a different biological approach, and the early data for retatrutide helped justify further studies. Receptor count alone does not establish greater benefit or fewer side effects.

How Does Retatrutide Work?

To understand the rationale for Retatrutide, it helps to look at what each of its three receptor targets does:

• GLP-1 (glucagon-like peptide-1) is the receptor targeted by medications like Ozempic and Wegovy. Activating GLP-1 receptors generally slows digestion, reduces appetite, and increases feelings of fullness. This is essentially the “brake” on calorie intake, as it makes you eat less by helping you feel satisfied sooner and for longer after meals.
• GIP (glucose-dependent insulinotropic polypeptide) is the second receptor. GIP is an incretin hormone involved in glucose-dependent insulin release. Researchers are investigating how activating GIP together with GLP-1 and glucagon affects blood sugar and body weight. This mechanism does not mean nausea is prevented or that aggressive dosing is safe.
• Glucagon is where Retatrutide breaks new ground. Glucagon helps regulate glucose and energy metabolism. Researchers are studying whether glucagon-receptor activity contributes to changes in liver fat and energy use, including boosting metabolic rate. Animal findings about increased energy expenditure do not establish how much energy retatrutide makes a person burn.

The Triple-Agonist Impact

The triple agonist approach is intended to combine effects on appetite, blood sugar and energy metabolism in a single molecule. Studies in animals found reduced food intake and increased energy expenditure. Human trials measure weight and health outcomes, but do not establish a guaranteed calorie-burning effect for an individual.

One important question with glucagon is whether its tendency to raise blood sugar creates problems. Clinical trial data so far has been reassuring, as the blood-sugar-lowering effects of the GLP-1 and GIP components appear to more than offset glucagon’s glucose-raising activity (in patients with Type 2 diabetes, retatrutide actually lowered blood sugar levels significantly).

An Overview of the Retatrutide Research

Eli Lilly is studying retatrutide through the TRIUMPH Phase 3 clinical trial program, including studies in people with obesity, Type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. 

Below is a summary of the key findings in the Retatrutide research so far.

How Much Weight Might People Lose With Retatrutide?

The most striking data comes from the TRIUMPH-4 Phase 3 trial, which studied 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. At 68 weeks, average weight loss with 12 mg was 28.7% versus 2.1% with placebo in the efficacy analysis; the treatment-regimen analysis reported 23.7% versus 4.6%. The latter includes outcomes regardless of treatment adherence. These are group averages from Lilly’s report.

For context, separate obesity trials reported average weight loss of 14.9% with semaglutide 2.4 mg at 68 weeks and 20.9% with tirzepatide 15 mg at 72 weeks. These figures are from different studies, populations and methods. They do not establish retatrutide’s superiority to either drug or equivalence to bariatric surgery.

It’s also worth noting that in an earlier Phase 2 trial, average weight loss at 48 weeks was 24.2% with 12 mg versus 2.1% with placebo. That trial enrolled 338 adults. The separate Phase 2 and Phase 3 results cannot tell an individual how much additional weight they will lose with longer treatment.
Lilly also reported TRIUMPH-2 and TRIUMPH-3 results in July 2026: at 80 weeks, average weight loss with 12 mg was 20.8% versus 4.0% with placebo in participants with overweight or obesity and Type 2 diabetes, and 22.6% versus 3.2% in those with severe obesity and established cardiovascular disease. These are efficacy-analysis results. Full TRIUMPH-2 results were subsequently presented and published in September 2026. These studies do not establish protection from heart attacks or strokes.

Does Retatrutide Help With Other Health Conditions?

Beyond weight loss, the retatrutide research points to several secondary benefits.

• Osteoarthritis-Related Pain – In the TRIUMPH-4 trial, participants experienced a big reduction in knee pain scores, with 12.0% of the 12 mg group reporting no knee pain, compared with 4.2% with placebo at 68 weeks in an exploratory post-hoc analysis. This result does not establish which biological mechanism caused the improvement.
• Fatty liver disease – In Phase 2 trials, 86% of participants assigned 12 mg had MRI-measured liver fat below 5% at 24 weeks in a 98-participant substudy. That imaging threshold is not proof that liver inflammation or scarring resolved, or that retatrutide cures MASH.

A large-scale trial (TRIUMPH-OUTCOMES) regarding Retatrutide’s impact on cardiovascular and kidney outcomes is studying these outcomes. Weight loss and improved risk markers do not themselves prove cardiovascular or kidney protection.

How Does Retatrutide in Canada Compare to Other Weight Loss Medications?

With several GLP-1 medications now available and in development, it helps to understand where Retatrutide in Canada fits. 

Here’s how Retatrutide compares to the major options available to Canadians.

Retatrutide vs. Ozempic/Wegovy (Injectable Semaglutide)

Semaglutide targets GLP-1 only. In STEP 1, semaglutide 2.4 mg produced 14.9% average weight loss versus 2.4% with placebo at 68 weeks in adults with overweight or obesity without diabetes. This was the obesity-treatment dose studied for Wegovy, not a result for every Ozempic dose. Retatrutide’s higher percentage in a separate trial is not a head-to-head comparison.

Health Canada has already approved generic semaglutide products in 2026, including a generic of Wegovy for weight management. Approval, pharmacy supply, price and insurance coverage are separate questions. A weight-loss plateau on semaglutide does not establish that switching to investigational retatrutide would be safe or effective.

Retatrutide vs. Mounjaro/Zepbound (Injectable Tirzepatide)

Tirzepatide is a close mechanistic comparator because it targets two of Retatrutide’s three receptors (GLP-1 and GIP). In SURMOUNT-1, adults with obesity or overweight without diabetes lost an average of 20.9% with tirzepatide 15 mg versus 3.1% with placebo at 72 weeks. Comparing that with a separate retatrutide trial cannot establish superiority or predict an extra number of pounds from switching. Mounjaro and Zepbound contain the same ingredient but have product-specific approved uses.

Retatrutide vs. Orforglipron (Oral GLP-1)

Orforglipron is Lilly’s oral GLP-1 receptor agonist. It is taken as a daily pill, whereas retatrutide is being studied as a weekly injection. The U.S. FDA approved orforglipron as Foundayo in April 2026, with no food or water restrictions. A U.S. decision does not establish Canadian approval or availability; this article does not predict a Canadian launch date.

Route of administration is a practical difference, but percentages from separate trials do not tell us which treatment is best for a particular patient. Treatment choice depends on the evidence for a particular product, its approved uses, benefits and risks, and the individual’s health needs.

Common Side Effects of Retatrutide

Like all GLP-1 medications, Retatrutide’s most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be dose-dependent and most pronounced during the early weeks of treatment when the dose is being gradually increased. 

Clinical trials used supervised dose escalation to assess tolerability. In Phase 2, gastrointestinal effects were generally dose-related and mostly mild to moderate; a lower starting dose reduced some of these effects. This is research information, not an approved Canadian dosing schedule.

Additional Retatrutide Side Effects

Clinical trials have also reported altered skin sensation and increased heart rate. These observations do not establish that the glucagon component caused them.

• Skin sensitivity (dysesthesia) – In the TRIUMPH-4 trial, 20.9% of participants at 12 mg versus 0.7% with placebo reported dysesthesia—an abnormal sense of touch that can include tingling or unusual skin sensitivity. Most events were mild. Overall discontinuation due to adverse events was 18.2% at 12 mg versus 4.0% with placebo; that rate includes all adverse events, not just dysesthesia.
• Heart rate increases – Clinical trials have shown a dose-dependent increase in resting heart rate, peaking around 24 weeks before declining in Phase 2. Longer-term outcomes research is needed to assess the clinical implications; substantial weight loss should not be assumed to cancel this risk or establish cardiovascular protection.

As with all weight loss medications, if Retatrutide in Canada becomes a treatment option, your doctor will discuss side effects and risks of the medication.

When Will Retatrutide Be Available in Canada?

Retatrutide is not approved by Health Canada. Lilly Canada’s August 13, 2026 public safety notice confirms that it cannot lawfully be sold to consumers. Lilly’s September 2026 update continues to describe retatrutide as investigational and available only in its clinical trials.

Lilly reported plans for a U.S. FDA submission in the first quarter of 2027. That is a planned U.S. submission, not a Canadian approval or launch date. No confirmed Canadian pharmacy availability date can be given.

How Much Will Retatrutide Cost in Canada?

Pricing for Retatrutide in Canada has not been announced. Because it is not an approved pharmacy treatment, there is no verified Canadian retail price to quote.

For an available medicine, the amount a patient pays depends on the specific product, dose, dispensing fees and insurance. Generic semaglutide approvals do not establish a future retatrutide price. Ask a licensed pharmacist for a quote for an actual prescribed product.

No Canadian retatrutide coverage decision is established here. Private-plan authorization and provincial formulary listing are separate decisions; coverage for another medicine or indication does not guarantee future retatrutide coverage.

Retatrutide Canada FAQs

What is Retatrutide?

Retatrutide is an investigational weekly injectable weight loss medication developed by Eli Lilly. It’s a triple agonist that targets GLP-1, GIP, and glucagon receptors. Its benefits and risks remain under study.

What is the Retatrutide dosage?

Retatrutide has been studied as a weekly injection, including 12 mg maintenance groups in the trials described above. There is no approved Canadian prescribing schedule. Trial doses are not instructions for self-injection, mixing a vial or escalating a dose.

Is Retatrutide available in Canada?

No. Retatrutide remains investigational and is not approved by Health Canada. A Canadian approval or pharmacy launch date has not been confirmed.

Can you switch from Ozempic or Mounjaro to Retatrutide?

There is no approved Canadian switching regimen for retatrutide. Shared receptor activity is not enough to establish that a transition is safe. Do not stop or change a prescribed treatment to use an unapproved product; discuss concerns or a plateau with your prescriber.

Where can I buy Retatrutide in Canada?

Retatrutide is not currently available for purchase in Canada. Any products sold online claiming to be Retatrutide are not approved by Health Canada and may not be safe. Approval is not guaranteed. Lilly says retatrutide should only be used in its sponsored clinical trials, where safety and effectiveness are being evaluated.

Should Patients Wait for Retatrutide or Get Treatment Now?

There is no confirmed Canadian retatrutide launch date to wait for. People with weight-management concerns can discuss available treatments with a healthcare professional now. Approved obesity treatments include Wegovy and Zepbound; whether medication is appropriate depends on an individual assessment. Ozempic and Mounjaro have product-specific indications and should not be treated as interchangeable with their obesity-treatment counterparts.

The first step in evaluating medical weight loss treatments is speaking with a suitably trained healthcare professional. A doctor can help you evaluate the treatment options currently available, which might be most suitable for your overall health situation and goals, and develop a strategy that includes lifestyle changes alongside any medication.

Walk In connects eligible patients in selected Metro Vancouver communities with physicians for phone or video appointments. The physician provides medical care and determines whether a prescription or in-person assessment is appropriate. Check current eligibility and appointment availability before booking. Booking does not provide access to retatrutide or guarantee a prescription.

Speak With a Virtual Doctor About Weight Loss Treatment